Non-metastatic high-risk prostate cancer patients with biochemical relapse only after local treatment. A prospective randomized phase III study comparing hormonal therapy +/--docetaxel.

Trial Profile

Non-metastatic high-risk prostate cancer patients with biochemical relapse only after local treatment. A prospective randomized phase III study comparing hormonal therapy +/--docetaxel.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 04 Jun 2013

At a glance

  • Drugs Docetaxel (Primary) ; Triptorelin
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Jun 2013 Quality-of-life results presented at the 49th Annual Meeting of the American Society of Clinical Oncology.
    • 07 Jun 2011 Final results for PSA-progression-free survival presented at the 47th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top